| October 1 |
Bayer ’s Novel Anticoagulant Xarelto Now Also Approved in the EU |
| October 1 |
Florida Attorney General Sues Merck for Misleading State Agencies Over Drug Marketing |
| October 2 |
Bayer's Novel Oral Anticoagulant Xarelto (Rivaroxaban) Gets European Licence |
| October 2 |
Watson Notified of OXYTROL Patent Challenge |
| October 2 |
Biotech Holdings Ltd. Announces Strategic Review Process |
| October 2 |
New Survey Reveals Consumers Wary of Prescription Switches |
| October 2 |
Merck Discontinues Development of Investigational Medicine Taranabant for Obesity |
| October 2 |
Physicians Interactive Acquired by Private Investment Firm Perseus L.L.C. |
| October 2 |
U.S. Food & Drug Administration Approved the use of REYATAZ (atazanavir sulfate) Boosted with Ritonavir, in Combination Therapy, for Previously Untreated HIV-1 Infected Adult Patients |
| October 2 |
PPD Completes Acquisition of InnoPharm |
| October 3 |
Genentech Issues Dear Healthcare Provider Letter Regarding a Reported Case of PML in a Raptiva Patient |
| October 3 |
Cardinal Health Resolves Controlled Substance License Suspensions |
| October 3 |
Severe Adverse Event Reported in Raptiva Patient |
| October 3 |
Cardinal Health Inc., Agrees to Pay $34 Million to Settle Claims That it Failed to Report Suspicious Sales of Widely-Abused Controlled Substances |
| October 3 |
District Court Affirms Patent Infringement Rulings and Finds That Amgen is Entitled to a Permanent Injunction against Roche |
| October 6 |
Ariad Announces Favorable Ruling Permitting Immediate Appeal of District Court Findings on NF-(kappa)B Patent in Amgen Litigation |
| October 6 |
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction |
| October 6 |
Waterfront Media To Merge With Revolution Health Network Establishing The Everyday Health Network As The Preeminent Online Health Destination |
| October 6 |
Landmark COPD Trial UPLIFT Shows SPIRIVA HandiHaler Sustained Lung Function Improvements Over Four Years |
| October 6 |
Westaim enters into reorganization agreement valuing Westaim at $0.60 per share |
| October 7 |
Anti-Cancer Drug Prevents, Reverses Cardiovascular Damage In Mouse Model Of Premature Aging Disorder |
| October 7 |
Eli Lilly and Company Resolves Investigation Involving Numerous States |
| October 7 |
AtheroGenics Files for Chapter 11 Bankruptcy |
| October 7 |
MedWatch - Tiotropium (Spiriva): updated information on risk of stroke and reports of cardiovascular adverse outcomes |
| October 8 |
FDA Issues BayerHealthCare Pharmaceuticals, Inc. Warning Letter for Yaz |
| October 8 |
Genmab Reports Results of Portfolio Review |
| October 9 |
EpiCept Receives Ceplene Marketing Approval in Europe |
| October 9 |
Novo Nordisk Assigns Inhaled Insulin Patent Portfolio to Aradigm |
| October 9 |
Shionogi and Sciele Announce Completion of Subsequent Offering Period |
| October 9 |
Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR |
| October 9 |
Boston Scientific Comments on Involuntary Selling of Its Stock by Co-Founders |
| October 9 |
Abbott Opens New Research Facility and Pilot Plant in Ludwigshafen |
| October 9 |
Canadian Vaccine Manufacturer Able to Deliver Doses Ahead of Schedule |
| October 9 |
AstraZeneca's Purplepill.com Tops the List of Most Visited Pharmaceutical Brand Web Sites in Q2 2008 |
| October 9 |
Omrix Biopharmaceuticals Provides Update On Fibrin Pad U.S. Phase II Clinical Trial In Mild to Moderate Bleeding |
| October 10 |
FDA Continues Review of Takeda's New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes |
| October 10 |
Shionogi Completes Acquisition of Sciele |
| October 10 |
Nation's Teen Vaccination Coverage Increasing, But Below 2010 Goals |
| October 10 |
FDA Approves AstraZeneca’s Seroquel XR for the Treatment of Bipolar Depression and Bipolar Mania in the US |
| October 13 |
King Pharmaceuticals Extends Tender Offer to Acquire Alpharma |
| October 13 |
AstraZeneca Survey: Physicians Play Critical Role in Helping Patients Take Medicines as Prescribed |
| October 13 |
Statins May Prevent Miscarriages |
| October 13 |
CSL Receives FTC Request for Additional Information on its Proposed Merger with Talecris Biotherapeutics |
| October 14 |
Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share |
| October 14 |
Par Pharmaceutical Announces Resizing of Generic Unit to Optimize Strong First-to-File Pipeline |
| October 14 |
Manhattan Research Announces Top Condition Groups Shifting Their TV Viewing Online |
| October 14 |
Johnson & Johnson Reports 2008 Third-Quarter Results |
| October 15 |
Abbott Reports Strong Sales and Earnings Growth in Third Quarter; Again Raises Full-Year Earnings Outlook |
| October 15 |
Genentech Announces Third Quarter 2008 Results |
| October 15 |
Alcon Announces Two Agreements Designed to Expand Its Future Drug Portfolio |
| October 15 |
Emory Creates New Conflict Oversight, Announces New Disclosure Requirements |
| October 15 |
Wyeth Provides Regulatory Update Regarding Desvenlafaxine for the Treatment of Major Depressive Disorder |
| October 15 |
GSK’s Emerging Markets Strategy Advances With Acquisition in Egypt |
| October 15 |
ETHEX Corporation Voluntarily Recalls Three Lots of Dextroamphetamine Sulfate 5mg Tablets Due to the Potential for Oversized Tablets |
| October 16 |
FDA Grants Full Approval to Ontak (denileukin diftitox) for Use in Patients with Cutaneous T-Cell Lymphoma (CTCL) |
| October 16 |
Cell Genesys Announces Termination of VITAL-1 Phase 3 Trial of GVAX Immunotherapy for Prostate Cancer |
| October 16 |
Baxter Posts Strong Sales and Earnings for Third Quarter 2008 |
| October 16 |
Dingell, Stupak Continue DTC Ad Investigation |
| October 16 |
Barr Says Court of Appeals Upholds 2005 District Court Decision on 1997 Cipro Settlement |
| October 17 |
FDA Approves Updated Labeling for Psoriasis Drug Raptiva |
| October 17 |
Pfizer Reaches Agreements in Principle to Resolve Litigation Involving Its NSAID Pain Medications |
| October 17 |
HHS Preparing to Open FDA Offices in China, India, Europe, and Latin America This Year |
| October 17 |
Plaintiffs' Counsel Comments On Settlement in Bextra Marketing, Sales Practices, and Product Liability Litigation |
| October 20 |
Novartis Delivers Sustained Strong Performance In First Nine Months Of 2008 Underpinned By Accelerating Growth In Pharmaceuticals |
| October 20 |
Adventrx Announces Restructuring and Cost Reduction Initiatives |
| October 20 |
HLTH Corporation and WebMD Health Corp. Announce Termination of Merger Agreement |
| October 20 |
Wisconsin Medical Society Board Passes New Physician Gift Policy |
| October 21 |
Pfizer Reports Third-Quarter 2008 Results |
| October 21 |
Biogen Idec Reports Third Quarter 2008 Results |
| October 21 |
Schering-Plough Reports Financial Results for Third Quarter of 2008 |
| October 21 |
Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder |
| October 21 |
Myriad Genetics Announces Plan to Separate Into Two Independent Public Companies |
| October 21 |
Novartis to Acquire Nektar Therapeutics Pulmonary Business Unit, Strengthening Respiratory Drug Delivery Capabilities |
| October 21 |
Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80 |
| October 21 |
Kyowa Hakko Kirin Revises Down Profit Forecasts: Full Year Sales Forecast Unchanged |
| October 21 |
Trimeris Reports Third Quarter 2008 Fuzoeon Sales Results |
| October 21 |
Lilly to Take Charge to Earnings Related to Pending Federal and State Investigations of Past Practices |
| October 21 |
Study Documents Safety Problems for Biological Products |
| October 22 |
Pfizer Names New Head of Clinical Development and Medical Affairs for Its Oncology Business Unit |
| October 22 |
Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months |
| October 22 |
Merck Reports Third-Quarter 2008 Financial Results |
| October 22 |
Dynavax and Merck & Co., Inc. Provide Update on U.S. FDA Clinical Hold on Investigational Vaccine HEPLISAV(TM) |
| October 22 |
Everyday Health Network Enters Content Alliance with Yahoo! |
| October 22 |
Genzyme Reports Strong Third-Quarter Sales and Earnings Growth |
| October 22 |
GSK delivers Q3 business performance EPS of 25.2p and increased dividend of 14p |
| October 22 |
Pfizer Completes Settlement Agreements with State Attorneys General Regarding its NSAID Pain Medications |
| October 23 |
Alcon's Third Quarter Sales Rise 14.1 Percent |
| October 23 |
Lilly Reports Third-Quarter Results |
| October 23 |
New Hope for Multiple Sclerosis Sufferers |
| October 23 |
Bristol-Myers Squibb Continues Excellent Financial Performance Led By Double-Digit Global Net Sales Growth and Strong Earnings Results |
| October 23 |
GlaxoSmithKline and Affiris Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimer's Disease Candidate Vaccines |
| October 23 |
Maxygen Announces Plans to Reduce Spending and Revise Corporate Strategy |
| October 23 |
Publicis Healthcare Communications Group (PHCG) Acquires Reed Weir Communications Strengthening its Offering in Australia and APAC |
| October 23 |
New President Named at Dorland Global Public Relations |
| October 23 |
First Centralised Authorisation To Be Moved To Non-Prescription Status |
| October 24 |
Further Clinical Trials in Osteoarthritis Pain Suspended for GRC 6211 |
| October 24 |
To Today's Drug Reps, Docs Just Say No |
| October 24 |
Astellas Announces the Withdrawal of EU MAA for Telavancin for Complicated Skin and Soft Tissue Infections |
| October 27 |
Q3/2008: Merck Total Revenues Increase 8.7% to € 1.9 Billion |
| October 27 |
Osteoporosis Drugs Increase Risk for Heart Problems |
| October 27 |
Johnson & Johnson Establishes Wellness & Prevention Platform with Acquisition of HealthMedia, Inc. |
| October 28 |
Meta-Analysis Examines Cardiovascular Effects of Diabetes Medications |
| October 28 |
Researchers: Strengthen Restrictions on Off-Label Promotion by Pharmaceutical Companies |
| October 28 |
Costlier New Diabetes Drugs Don't Necessarily Produce Better Outcomes, Stanford Researcher Says |
| October 28 |
How Drug Companies Covertly Promote Off-Label Drug Use |
| October 28 |
Credit Crunch Threatens New Medicines |
| October 28 |
First Online Drug Alerts Go to U.S. Doctors |
| October 28 |
Harvest Technologies Announces Patient Education Website, www.CLIclinicalstudy.com |
| October 29 |
Bayer Optimistic About Future Business Trend |
| October 29 |
Merck KGaA Announces Collaboration and Licensing Agreement with Theratechnologies for Tesamorelin in the United States |
| October 29 |
IMS Health Forecasts 4.5 - 5.5 Percent Growth for Global Pharmaceutical Market in 2009, Exceeding $820 Billion |
| October 29 |
Allergan Reports Third Quarter 2008 Operating Results |
| October 29 |
Shire's New Product Portfolio Delivers Strong Quarterly Performance |
| October 29 |
Growing Number of Consumers Trust Online Resources Over Other Media for Researching Drug Treatment Information – Prospectiv Survey Reveals |
| October 30 |
GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C |
| October 30 |
AstraZeneca PLC:Third Quarter and Nine Months Results 2008 |
| October 30 |
FDA Sends Letter to Amgen Over Sensipar DTC Brochure |
| October 30 |
Americans Dissatisfied with Healthcare, Want Lower Costs Even if it Means Sacrificing Quality According to New QualityHealth.com Survey |
| October 31 |
Schering-Plough to Appeal Jury Decision in Missouri Reimbursement Case |
| October 31 |
GSK Believes There Is No Liver Safety Issue With Avandia; Responds to Public Citizen Petition |
| October 31 |
Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): |
